TY - JOUR
T1 - Cannabis use in people with severe mental illness: The association with physical and mental health - a cohort study
T2 - A Pharmacotherapy Monitoring and Outcome Survey study
AU - Bruins, Jojanneke
AU - Pijnenborg, Marieke Gh
AU - Bartels-Velthuis, Agna A
AU - Visser, Ellen
AU - van den Heuvel, Edwin R
AU - Bruggeman, Richard
AU - Jörg, Frederike
N1 - © The Author(s) 2016.
PY - 2016/4
Y1 - 2016/4
N2 - Objective: In the general population cannabis use is associated with better cardiometabolic outcomes. Patients with severe mental illness frequently use cannabis, but also present increased cardiometabolic risk factors. We explore the association between cannabis use and cardiometabolic risk factors in patients with severe mental illness.Method: A total of 3169 patients with severe mental illness from a Dutch cohort were included in the study. The association of cannabis use with body mass index, waist circumference, blood pressure, cholesterol, triglycerides, glucose, glycated hemoglobin and Positive and Negative Syndrome Scale was examined with separate univariate AN(C)OVA. Changes in metabolic risk factors and Positive and Negative Syndrome Scale were examined after a follow-up interval of 9-24 months, for patients who continued, discontinued, started or were never using cannabis between the two assessments.Results: Cannabis users at baseline had lower body mass index, smaller waist circumference, lower diastolic blood pressure, and more severe psychotic symptoms than non-users. Patients who discontinued their cannabis use after the first assessment had a greater increase in body mass index, waist circumference, diastolic blood pressure and triglyceride concentrations than other patients, and the severity of their psychotic symptoms had decreased more compared to continued users and non-users.Conclusion: Extra attention should be paid to the monitoring and treatment of metabolic parameters in patients who discontinue their cannabis use.
AB - Objective: In the general population cannabis use is associated with better cardiometabolic outcomes. Patients with severe mental illness frequently use cannabis, but also present increased cardiometabolic risk factors. We explore the association between cannabis use and cardiometabolic risk factors in patients with severe mental illness.Method: A total of 3169 patients with severe mental illness from a Dutch cohort were included in the study. The association of cannabis use with body mass index, waist circumference, blood pressure, cholesterol, triglycerides, glucose, glycated hemoglobin and Positive and Negative Syndrome Scale was examined with separate univariate AN(C)OVA. Changes in metabolic risk factors and Positive and Negative Syndrome Scale were examined after a follow-up interval of 9-24 months, for patients who continued, discontinued, started or were never using cannabis between the two assessments.Results: Cannabis users at baseline had lower body mass index, smaller waist circumference, lower diastolic blood pressure, and more severe psychotic symptoms than non-users. Patients who discontinued their cannabis use after the first assessment had a greater increase in body mass index, waist circumference, diastolic blood pressure and triglyceride concentrations than other patients, and the severity of their psychotic symptoms had decreased more compared to continued users and non-users.Conclusion: Extra attention should be paid to the monitoring and treatment of metabolic parameters in patients who discontinue their cannabis use.
KW - Cannabis
KW - metabolic syndrome
KW - psychotic disorders
KW - PANSS
KW - severe mental illness
KW - BODY-MASS INDEX
KW - MARIJUANA USE
KW - FOLLOW-UP
KW - SOCIOECONOMIC-STATUS
KW - INSULIN-RESISTANCE
KW - METABOLIC SYNDROME
KW - ENERGY-BALANCE
KW - SUBSTANCE USE
KW - RISK-FACTOR
KW - SCHIZOPHRENIA
U2 - 10.1177/0269881116631652
DO - 10.1177/0269881116631652
M3 - Article
C2 - 26883305
SN - 0269-8811
VL - 30
SP - 354
EP - 362
JO - Journal of Psychopharmacology
JF - Journal of Psychopharmacology
IS - 4
ER -